Stanford University; Dickinson College, B.A., 1984
Law School Attended:
Duquesne University, J.D., 1987
Year of First Admission:
Delaware; U.S. District Court, Eastern District of Pennsylvania; U.S. District Court, District of Delaware; District of Columbia; U.S. District Court, Western District of Pennsylvania; U.S. Court of Appeals, Third Circuit; United States Supreme Court; New Jersey; Pennsylvania; U.S. District Court, Middle District of Pennsylvania; U.S. District Court, District of New Jersey; U.S. Court of Claims; Massachusetts; New York
Dion G. Rassias, Esquire of The Beasley Firm, LLC recently filed Complaints on behalf of Plumbers' Local Union No. 690 Health Plan (“Local 690”) and the Delaware Valley Health Care Coalition (“DVHCC”) seeking over $1 billion in damages from several generic drug manufacturers who have increased the prices of generic drugs at alarming rates. Both Complaints show that the plaintiffs purchase or reimburse the cost of prescription drugs for their members, and as a result of the defendant generic drug companies' “unfair and deceptive acts and practices,” plaintiffs and their members dramatically and drastically overpaid for these medications. These deceptive practices affect many types of healthcare patients including “government assistance patients” (those who are members of one or more government assistance programs which cover all or part of the cost of their generic prescription drugs, including Medicare, Medicaid, and PACE), “private assistance patients” (those who are members of private health insurance plans offered by union funds and other self-funded third party payors for full or the partial payment of their generic prescription drugs), and “no assistance patients” (those who have no health insurance at all for the payment of their generic prescription drugs, and thus have to pay cash for their generic prescription drugs based upon inflated “average wholesale prices” (“AWPs”) for such drugs). These patients, and those that provide them with generic prescription drug benefits, all paid more for generic prescription drugs than they should have paid as a result of the schemes of the defendants.